Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 21.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 9.00K | 0.00 | -273.00K | -240.00K | -79.00K | -60.00K |
EBITDA | -386.26M | -384.66M | -134.46M | -99.84M | -90.19M | -49.50M |
Net Income | -386.67M | -367.08M | -142.19M | -102.03M | -90.12M | -49.50M |
Balance Sheet | ||||||
Total Assets | 685.03M | 478.69M | 596.27M | 196.82M | 162.42M | 211.07M |
Cash, Cash Equivalents and Short-Term Investments | 638.78M | 439.95M | 578.87M | 188.16M | 150.75M | 204.65M |
Total Debt | 1.64M | 37.55M | 27.11M | 20.05M | 19.40M | 0.00 |
Total Liabilities | 79.57M | 77.90M | 59.96M | 44.99M | 36.47M | 8.11M |
Stockholders Equity | 605.46M | 400.79M | 536.31M | 151.83M | 125.96M | 202.96M |
Cash Flow | ||||||
Free Cash Flow | -399.93M | -367.84M | -129.19M | -81.10M | -76.84M | -46.37M |
Operating Cash Flow | -399.84M | -367.82M | -129.19M | -81.09M | -76.78M | -46.24M |
Investing Cash Flow | 31.20M | -40.86M | -123.02M | -33.94M | 7.16M | -106.83M |
Financing Cash Flow | 466.46M | 218.59M | 513.11M | 117.83M | 23.87M | 157.92M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $932.01M | ― | -56.31% | ― | ― | -106.10% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
50 Neutral | $750.63M | ― | -44.59% | ― | -73.79% | -5.24% | |
48 Neutral | $885.20M | ― | -63.17% | ― | -40.51% | -35.07% | |
43 Neutral | $934.88M | 2.31 | -50.47% | ― | -100.00% | 94.68% | |
42 Neutral | $1.42B | ― | -69.30% | ― | ― | -68.13% | |
36 Underperform | $1.22B | ― | -31.30% | ― | ― | 12.85% |
On April 9, 2025, 89bio released an updated corporate presentation detailing the progress of their product candidate, pegozafermin, which is currently in late-stage clinical trials for MASH and SHTG. The company highlights pegozafermin’s potential as a best-in-class therapy with a favorable safety profile and robust market opportunities. The presentation outlines the anticipated timelines for clinical trial results and commercialization, emphasizing a strong financial position with significant cash reserves to support ongoing development and operations.
Spark’s Take on ETNB Stock
According to Spark, TipRanks’ AI Analyst, ETNB is a Neutral.
89bio’s stock reflects the high-risk, high-reward nature typical of early-stage biotech companies. The financial performance score is hampered by the lack of revenue and ongoing operational losses, despite a strong cash position. Technical analysis indicates bearish momentum, with potential volatility. The valuation score is low due to negative earnings and no dividend yield, common for firms in the R&D phase. Investors should be mindful of the company’s future reliance on successful R&D outcomes or additional financing.
To see Spark’s full report on ETNB stock, click here.